First Scale-Up: Problems and Resolutions on the Synthesis of WAY-253752, a Novel, Dual-Acting SSRI/5HT1A Antagonist
Organic Process Research & Development2007Vol. 12(1), pp. 76–80
Citations Over TimeTop 19% of 2007 papers
Antonia A. Nikitenko, Deborah A. Evrard, Annmarie L. Sabb, Robert L. Vogel, Gary Stack, Mairead Young, Melissa Lin, Boyd L. Harrison, John R. Potoski
Abstract
An alternative synthesis of WAY-253752, 1, a novel, dual-acting SSRI/5HT1A antagonist, was developed and used for the first scale-up. Initially, the target compound was synthesized as part of a diasteromeric mixture separated by chiral preparative HPLC. The new route was designed around intermediates suitable for chiral resolution, and its conditions were successfully determined.
Related Papers
- → Dual Trading in Futures Markets(1992)137 cited
- → Helix12-Stabilization Antagonist of Vitamin D Receptor(2016)20 cited
- → The Vedic Dual: Part VI, The Elliptic Dual; Part VII, The Dual Dvandva(1912)8 cited
- → The Changes of Serotonin (5HT‐1, 5HT‐1A, 5HT‐1B, 5HT‐2) Receptor Densities in Rat Brain Following Chronic Zotepine Treatment(1986)6 cited
- → Dual Training – a Good Solution to Current Socio-economic Problems(2021)